How is amycretin different from CagriSema?

CagriSema is two molecules combined. Amycretin is one molecule that binds both receptors, which is harder to design but avoids having to match two pharmacokinetic profiles.

Is amycretin approved anywhere?

No. It completed Phase 2 and is advancing into Phase 3.

Why does 'no plateau at week 36' matter?

It means weight reduction was still continuing when the trial ended, so the reported figure reflects the trial's length rather than the compound's limit.

GLP-1 & Incretin Science

What Is Amycretin? One Molecule, Two Receptors

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Amycretin is a unimolecular agonist of both the GLP-1 and amylin receptors developed by Novo Nordisk. Unlike CagriSema, which combines two separate molecules, amycretin engages both receptors from a single peptide. It exists in once-weekly subcutaneous and once-daily oral forms, and Phase 2 data reported up to 14.5% weight reduction at 36 weeks.

Key facts

Class: Unimolecular GLP-1 + amylin receptor agonist
Developer: Novo Nordisk
Formulations: Weekly subcutaneous and daily oral
Phase 2 population: 448 adults with type 2 diabetes
Duration: Up to 36 weeks
Subcutaneous result: 11.9% placebo-adjusted reduction
Oral result: 7.6% placebo-adjusted reduction
Status: Advancing to Phase 3

Unimolecular versus combination

This is the technically interesting part. CagriSema achieves amylin and GLP-1 agonism by putting two engineered peptides in one syringe. Amycretin achieves it with one peptide that binds both receptors. Unimolecular design removes the need to match the pharmacokinetics of two separate agents and simplifies manufacturing, but it is a much harder molecule to engineer — the same problem that makes retatrutide's triple agonism notable.

What the Phase 2 trial tested

The study enrolled 448 adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor. It was a combined multiple-ascending-dose design testing six weekly subcutaneous doses from 0.4 mg to 40 mg and three daily oral doses of 6 mg, 25 mg and 50 mg, over up to 36 weeks.

The results, and the detail worth noticing

Weight reduction reached up to 14.5% at 36 weeks against placebo, with the weekly subcutaneous formulation producing 11.9% placebo-adjusted reduction and the daily oral form 7.6%. The finding that attracted most attention was not the headline figure: at the higher doses, no weight-loss plateau had been reached by week 36 in either route. A curve that has not flattened at the end of a trial says the observed number is a floor for that duration, not a ceiling.

Tolerability

Adverse events were predominantly gastrointestinal and mostly mild to moderate, consistent with both the incretin and amylin classes. The profile was described as safe and well tolerated across both routes, though Phase 2 populations are small relative to what a full safety picture requires.

Why an oral form matters here

Amycretin is a peptide, so its daily oral form faces exactly the barriers that make oral peptides difficult — gastric acid, proteases, poor permeability. That an oral peptide route produced 7.6% placebo-adjusted reduction at all is the notable part, and it sits in direct contrast to orforglipron's approach of abandoning the peptide backbone entirely.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How is amycretin different from CagriSema?: CagriSema is two molecules combined. Amycretin is one molecule that binds both receptors, which is harder to design but avoids having to match two pharmacokinetic profiles.
Is amycretin approved anywhere?: No. It completed Phase 2 and is advancing into Phase 3.
Why does 'no plateau at week 36' matter?: It means weight reduction was still continuing when the trial ended, so the reported figure reflects the trial's length rather than the compound's limit.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum